BriaCell Therapeutics Corp.
BCTX · XNASCIK 1610820fmd_10Z7BCY8D6N1K94HTDDVW94E8WManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 30, 2018 to Jul 31, 2026, 28 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2021 | FY2022 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | – | 2 | – | 2 | – | 8 | 15 | 27 | 21 | 29 |
| Taxes other than income taxes | – | – | – | – | – | – | – | – | 1 | 1 |
| Total operating expenses | – | – | – | – | – | – | 23 | 33 | 27 | 36 |
| Operating income | – | (4) | – | (7) | – | (15) | (23) | (33) | (27) | (36) |
| Interest expense | – | – | – | 0 | – | 0 | – | – | 0 | 0 |
| Interest and investment income | – | – | – | 0 | – | 0 | 1 | 0 | 0 | 1 |
| Other non-operating income (expense) | – | – | – | (7) | – | (12) | 1 | 0 | 0 | 1 |
| Income before taxes | – | – | – | (14) | – | (27) | 20 | 5 | 27 | 35 |
| Income tax expense | – | – | 0 | – | 0 | – | – | – | – | – |
| Net income from continuing operations | – | – | – | (14) | – | (27) | – | – | – | – |
| Net income | (5) | (4) | – | (14) | – | (27) | (20) | (5) | (26) | (35) |
| Net income to common shareholders | – | – | – | (14) | – | (27) | (20) | (5) | (26) | (35) |